Lenvatinib continuation versus regorafenib in treating hepatocellular carcinoma after lenvatinib failure.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) represents a major global health burden. Despite lenvatinib's established role as first-line therapy for advanced HCC, the optimal sequential strategy after its failure remains uncertain. This study compared the efficacy and safety of lenvatinib continuation versus switching to regorafenib following first-line lenvatinib progression.

Methods

A retrospective analysis was conducted on 107 consecutive HCC patients treated with lenvatinib. Patients were divided into two groups based on their second-line treatment: the regorafenib group (LEN-RG, 49 patients) and the lenvatinib continuation group (LEN-CON, 58 patients). Baseline characteristics were collected, and overall survival (OS), post-progression survival (PPS), total progression-fr

SUBMITTER: Pan T 

PROVIDER: S-EPMC12780716 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature